Who Are the Core Customers of Vor Company?

Vor Company customers focus on the subset of roughly 20,000 new U.S. AML diagnoses annually, specifically the high – risk CD33 – positive patients eligible for allogeneic stem cell transplant who need a shielded immune system to tolerate post – transplant maintenance and reduce relapse rates.

Vor Company target customers include Tier 1 academic transplant centers and their hematologist – oncologists who manage cases with a current post – transplant relapse rate of 30% to 50% and who seek therapies that permit safer maintenance regimens.

Vor Company serves a mixed base: individual patients (through treating centers) and institutional buyers (academic medical centers, transplant programs) where procurement and clinical adoption decisions are made by hospital formularies and transplant teams.

The most commercially important segment is high – risk post – transplant AML patients at leading transplant centers, representing the bulk of early revenue potential as payers and centers evaluate post – transplant maintenance solutions; see Product Growth of Vor Company for related context: Product Growth of Vor Company

The US is the primary market because it performs ~9,000 allogeneic HSCTs annually, a substantial share for acute myeloid leukemia (AML); dense cell-therapy infrastructure and reimbursement pathways make it the largest concentration of Vor Company customers and Vor Company target customers.

EU4 (Germany, France, Italy, Spain) and the UK follow the US in demand: high-volume transplant centers and NCI-equivalent oncology hubs adopt novel cell-engineered maintenance therapies as they gain regulatory clarity.

Vor Company shows greatest traction in the maintenance therapy vertical where systemic-toxicity limits current standards of care; this aligns Vor Company primary revenue-generating customer types with transplant centers seeking lower-toxicity post-HSCT solutions.

As VBP101 advances through Phase 1/2, demand is rising among CAR-T programs that view engineered donor cells as a companion to improve safety and efficacy after transplant; this creates new Vor Company customer segments within cell-therapy centers and academic CAR-T units. See Leadership and Ownership of Vor Company for context.

Vor Company target customers grow as the platform adds targets beyond CD33-CD123 and CLL-1-opening access to acute lymphoblastic leukemia (ALL) subtypes, other acute myeloid leukemia (AML) cohorts, and myelodysplastic syndromes while staying within hematologic oncology.

Vor Company customers retain confidence because the company shields trem-cel as the backbone; concurrent internal CAR-T development such as VCAR33 complements rather than cannibalizes the core, preserving clinical and commercial continuity.

Repeat demand and ecosystem stickiness rise as hospital systems and specialty oncologists adopt a proprietary treatment pathway: engineered hematopoietic stem cell (HSC) protection plus matched CAR-Ts increases lifetime patient throughput and referral pull.

In 2026 Vor Company prioritized HSC engineering validation-this foundational tech enables multi-indication rollout and partner licensing, driving the biggest near-term expansion in addressable market and partnership deals; clinical validation reduces partner onboarding time and regulatory risk.